Northwind Pharmaceuticals,llc

Northwind Pharmaceuticals,llc Drugs

• Amoxicillan
  

  ×

  Amoxicillan

  

  ---

  VIEW THE MANUFACTURER'S COMPLETE DRUG INFORMATION AT THE FDA SITE HERE: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d42fbeff-dcca-447c-83e2-c59690b7dc1a

  THIS SITE LISTS ALL RECOMMENDED DOSAGE INFORMATION FOR THE VARIOUS MALADIES.

  Amoxicillin capsules may be given without regard to meals.

  Neonates and Infants Aged ≤ 12 Weeks (≤ 3 Months)

  Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin is 30 mg/kg/day divided q12h.

  All patients with gonorrhea should be evaluated for syphilis. (See PRECAUTIONS:Laboratory Tests section.)

  Larger doses may be required for stubborn or severe infections.

  General

  It should be recognized that in the treatment of chronic urinary tract infections, frequent bacteriological and clinical appraisals are necessary. Smaller doses than those recommended above should not be used. Even higher doses may be needed at times. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy. Except for gonorrhea, treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days’ treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever.

  H. pyloriEradication to Reduce the Risk of Duodenal Ulcer Recurrence

  Triple Therapy

  Amoxicillin/Clarithromycin/Lansoprazole

  The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (q12h) for 14 days. (See INDICATIONS AND USAGE section.)

  Dual Therapy

  Amoxicillin/Lansoprazole

  The recommended adult oral dose is 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (q8h) for 14 days. (See INDICATIONS AND USAGE section.)

  Please refer to clarithromycin and lansoprazole full prescribing information for CONTRAINDICATIONS and WARNINGS section, and for information regarding dosing in elderly and renally impaired patients.

  Dosing Recommendations for Adults with Impaired Renal Function

  Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Severely impaired patients with a glomerular filtration rate of < 30 mL/min should not receive the 875 mg tablet. Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection. Patients with a less than 10 mL/min glomerular filtration rate should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection.

  Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.

  There are currently no dosing recommendations for pediatric patients with impaired renal function.

  Close
  More Info
• Famotidine
  

  ×

  Famotidine

  

  ---

  Duodenal Ulcer

  Acute Therapy

  The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. A regimen of 20 mg b.i.d. is also effective.

  Maintenance Therapy

  The recommended adult oral dose is 20 mg once a day at bedtime.

  Benign Gastric Ulcer

  Acute Therapy

  The recommended adult oral dosage for active benign gastric ulcer is 40 mg once a day at bedtime.

  Gastroesophageal Reflux Disease (GERD)

  The recommended oral dosage for treatment of adult patients with symptoms of GERD is 20 mg b.i.d. for up to 6 weeks. The recommended oral dosage for the treatment of adult patients with esophagitis including erosions and ulcerations and accompanying symptoms due to GERD is 20 or 40 mg b.i.d. for up to 12 weeks (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies).

  Dosage for Pediatric Patients < 1 year of age Gastroesophageal Reflux Disease (GERD)

  See PRECAUTIONS, Pediatric Patients < 1 year of age.

  The studies described in PRECAUTIONS, Pediatric Patients< 1 year of age suggest the following starting doses in pediatric patients < 1 year of age: Gastroesophageal Reflux Disease (GERD) - 0.5 mg/kg/dose of famotidine oral suspension for the treatment of GERD for up to 8 weeks once daily in patients < 3 months of age and 0.5 mg/kg/dose twice daily in patients 3 months to < 1 year of age. Patients should also be receiving conservative measures (e.g., thickened feedings). The use of intravenous famotidine in pediatric patients < 1 year of age with GERD has not been adequately studied.

  Dosage for Pediatric Patients 1 to 16 years of age

  See PRECAUTIONS, Pediatric Patients1 to 16 years of age.

  The studies described in PRECAUTIONS, Pediatric Patients1 to 16 years of age suggest the following starting doses in pediatric patients 1 to 16 years of age:

  Peptic Ulcer

  0.5 mg/kg/day p.o. at bedtime or divided b.i.d. up to 40 mg/day.

  Gastroesophageal Reflux Disease With Or Without Esophagitis Including Erosions And Ulcerations

  1 mg/kg/day p.o. divided b.i.d. up to 40 mg b.i.d.

  While published uncontrolled studies suggest effectiveness of famotidine in the treatment of gastroesophageal reflux disease and peptic ulcer, data in pediatric patients are insufficient to establish percent response with dose and duration of therapy. Therefore, treatment duration (initially based on adult duration recommendations) and dose should be individualized based on clinical response and/or pH determination (gastric or esophageal) and endoscopy. Published uncontrolled clinical studies in pediatric patients 1 to 16 years of age have employed doses up to 1 mg/kg/day for peptic ulcer and 2 mg/kg/day for GERD with or without esophagitis including erosions and ulcerations.

  Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome, Multiple Endocrine Adenomas)

  The dosage of famotidine in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose for pathological hypersecretory conditions is 20 mg q 6 h. In some patients, a higher starting dose may be required. Doses should be adjusted to individual patient needs and should continue as long as clinically indicated. Doses up to 160 mg q 6 h have been administered to some adult patients with severe Zollinger-Ellison Syndrome.

  Concomitant Use of Antacids

  Antacids may be given concomitantly if needed.

  Dosage Adjustment for Patients with Moderate or Severe Renal Insufficiency

  In adult patients with moderate (creatinine clearance < 50 mL/min) or severe (creatinine clearance < 10 mL/min) renal insufficiency, the elimination half-life of famotidine is increased. For patients with severe renal insufficiency, it may exceed 20 hours, reaching approximately 24 hours in anuric patients. Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, to avoid excess accumulation of the drug in patients with moderate or severe renal insufficiency, the dose of famotidine may be reduced to half the dose or the dosing interval may be prolonged to 36 to 48 hours as indicated by the patient’s clinical response.

  Based on the comparison of pharmacokinetic parameters for famotidine in adults and pediatric patients, dosage adjustment in pediatric patients with moderate or severe renal insufficiency should be considered.

  Close
  More Info